Adverse effects analysis results during anti-TB treatment among hemodialysis patients

O. Gordeeva (Moscow, Russian Federation), N. Karpina (Moscow, Russian Federation), S. Andreevskaya (Moscow, Russian Federation), E. Larionova (Moscow, Russian Federation)

Source: Virtual Congress 2021 – Challenges and advances in the diagnosis and clinical management of tuberculosis

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
O. Gordeeva (Moscow, Russian Federation), N. Karpina (Moscow, Russian Federation), S. Andreevskaya (Moscow, Russian Federation), E. Larionova (Moscow, Russian Federation). Adverse effects analysis results during anti-TB treatment among hemodialysis patients. 1052

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Adverse effects of anti-tuberculosis drugs in hemodialysis patients
Source: International Congress 2019 – Tuberculosis and comorbidities
Year: 2019

Adverse events in patients with MDR TB, treated by three types of the chemotherapy regimens
Source: International Congress 2019 – Tuberculosis: treatment and management
Year: 2019

Management of adverse drug events in TB therapy
Source: Eur Respir Mon 2012; 58: 167-193
Year: 2012

Severe adverse effects of antitubercular drugs and patient management
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011

Adverse anti-tuberculosis drug events and their management
Source: Eur Respir Monogr 2018; 82: 205-227
Year: 2018

Adverse effects of MDR-TB treatment with a standardized regimen: A report from Iran
Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities
Year: 2010

Frequency of adverse reactions to first-line anti-tuberculosis chemotherapy in patients with relapse(RTB)and newly diagnosed tuberculosis(NDTB)
Source: International Congress 2018 – Challenges in tuberculosis care
Year: 2018

Frequent adverse events during prolonged Bedaquiline treatment on XDR-tuberculosis patients
Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II
Year: 2019

The safety of LAMA/LABA combination therapy for the ocular and urinary adverse effects in the COPD patients
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019

Adverse effects of second-line drugs during the treatment of multidrug resistant tuberculosis patients
Source: Eur Respir J 2005; 26: Suppl. 49, 650s
Year: 2005

Adverse effects of treatment in HIV-associated tuberculosis patients in Iran
Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts
Year: 2011

Cost analysis for patients with severe asthma receiving omalizumab treatment
Source: International Congress 2019 – Clinical aspects of airway diseases
Year: 2019

Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry
Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2020

Adverse drug reactions and outcomes of tuberculosis treatment using fixed-dose combination (FDC) regimen
Source: Annual Congress 2012 - Tuberculosis: clinical findings I
Year: 2012

Cardiovascular adverse effects during itraconazole therapy
Source: Eur Respir J 2008; 32: 240
Year: 2008

A prospective study of prevalence of adverse drug reactions to the short course anti-tuberculosis regimen in Korea
Source: Annual Congress 2007 - Epidemiological and clinical aspects of tuberculosis control
Year: 2007

Impact of adverse drug reactions on treatment interruption in TB patients with and without HIV coinfection
Source: ISSN=ISSN 1810-6838, ISBN=, page=190
Year: 2006

Adverse reactions to antituberculosis chemotherapy: tolerance versus intolerance
Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities
Year: 2009

Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations)
Source: Eur Respir J 2007; 30: Suppl. 51, 125s
Year: 2007